Abstract
Oral e-Poster Presentations - Booth 3: Neuro-Oncology A (Malignant glioma), September 25, 2023, 1:00 PM - 2:30 PM
Background: The benefit of regular, scheduled follow-up MRI on glioblastoma patient management and outcomes is unclear. Our aim was to investigate national follow-up MRI surveillance practice after surgery for glioblastoma, assess compliance with recommendations from the National Institute for Health and Care Excellence (NICE), and determine the association with overall survival (OS) and progression-free survival (PFS).
Methods: Multi-centre retrospective observational cohort study of histopathologically confirmed glioblastoma (operated August 2018-February 2019) who received any adjuvant oncological treatment. Follow-up MRI schedules, indications, and clinical outcomes were collected. Primary objective was to assess compliance with NICE recommendations (Post-operative scan < 72 hrs, MRI every 3-6 months). Secondary objectives were OS and PFS.
Results: 754 patients from 26 neuro-oncology centres were included. Most patients had post-operative MRI < 72 hours of surgery (88.1%, N=407/462). 28.1% of patients had follow-up MRI in accordance with NICE recommendations (N=212/754). Median follow-up period was 10.5 months (IQR 5.3-19.4 months). Median overall survival was 15.1 months (95% CI 12.9-17.3) in the scheduled MRI group and 9.1 months (95% CI 7.8-10.4) in the non-compliant group. On multivariable cox regression analysis, regular, scheduled MRI was independently associated with longer overall survival (HR 1.67, 95% CI 1.33-2.10, P < 0.001), but not PFS (HR 1.20, 95% CI 0.98-1.47, P=0.074). Having three or more scheduled scans in the first 12 months of follow-up was independently associated with increased OS (HR 2.03, 95% CI 1.41-2.94, P < 0.001) and PFS (HR 1.67, 95% CI 1.25-2.23, P < 0.001).
Conclusions: Following regular scheduled surveillance follow-up MRI for glioblastoma is associated with longer overall survival. Prospective trials are needed to determine whether regular or symptom-directed MRI influences survival outcomes and quality of life.
Background: The benefit of regular, scheduled follow-up MRI on glioblastoma patient management and outcomes is unclear. Our aim was to investigate national follow-up MRI surveillance practice after surgery for glioblastoma, assess compliance with recommendations from the National Institute for Health and Care Excellence (NICE), and determine the association with overall survival (OS) and progression-free survival (PFS).
Methods: Multi-centre retrospective observational cohort study of histopathologically confirmed glioblastoma (operated August 2018-February 2019) who received any adjuvant oncological treatment. Follow-up MRI schedules, indications, and clinical outcomes were collected. Primary objective was to assess compliance with NICE recommendations (Post-operative scan < 72 hrs, MRI every 3-6 months). Secondary objectives were OS and PFS.
Results: 754 patients from 26 neuro-oncology centres were included. Most patients had post-operative MRI < 72 hours of surgery (88.1%, N=407/462). 28.1% of patients had follow-up MRI in accordance with NICE recommendations (N=212/754). Median follow-up period was 10.5 months (IQR 5.3-19.4 months). Median overall survival was 15.1 months (95% CI 12.9-17.3) in the scheduled MRI group and 9.1 months (95% CI 7.8-10.4) in the non-compliant group. On multivariable cox regression analysis, regular, scheduled MRI was independently associated with longer overall survival (HR 1.67, 95% CI 1.33-2.10, P < 0.001), but not PFS (HR 1.20, 95% CI 0.98-1.47, P=0.074). Having three or more scheduled scans in the first 12 months of follow-up was independently associated with increased OS (HR 2.03, 95% CI 1.41-2.94, P < 0.001) and PFS (HR 1.67, 95% CI 1.25-2.23, P < 0.001).
Conclusions: Following regular scheduled surveillance follow-up MRI for glioblastoma is associated with longer overall survival. Prospective trials are needed to determine whether regular or symptom-directed MRI influences survival outcomes and quality of life.
| Original language | English |
|---|---|
| Article number | 102127 |
| Number of pages | 1 |
| Journal | Brain and Spine |
| Volume | 3 |
| Issue number | Supplement 1 |
| DOIs | |
| Publication status | Published - 26 Sept 2023 |
| Event | EANS2023 Annual Congress - Barcelona, Spain Duration: 24 Sept 2023 → 28 Sept 2023 |